Kunkel M J, Iannini P B, Landes R, Harrison L, Wells G, Snow R, Schaeffer A J, Goldstein E J, Berman S
Department of Infectious Diseases, Danbury Hospital, Conn.
Eur Urol. 1990;17 Suppl 1:30-3. doi: 10.1159/000464088.
One hundred thirty-one patients of urologists and infectious disease specialists were entered into an open trial of norfloxacin in the therapy of urinary tract infections (UTIs). All patients were evaluable for tolerability and 98 were evaluable for efficacy. The patient population in this study was older (mean age 53 years) and had more underlying urogenital disorders (30%) or recent invasive urologic procedures (20%) than the typical patient population with UTIs. Over 50% of the patients had infections due to organisms other than Escherichia coli, including Pseudomonas aeruginosa (14), Klebsiella pneumoniae (5), Enterobacter spp (3) and Group D streptococcus (6). Clinical and bacteriologic cure rates were 90 and 91%, respectively. Side effects occurred in 5 patients and were generally mild.
131名泌尿科医生和传染病专家的患者参与了诺氟沙星治疗尿路感染（UTIs）的开放试验。所有患者均可评估耐受性，98名患者可评估疗效。本研究中的患者群体年龄较大（平均年龄53岁），与典型的UTIs患者群体相比，有更多潜在的泌尿生殖系统疾病（30%）或近期侵入性泌尿外科手术史（20%）。超过50%的患者感染病原体为大肠埃希菌以外的其他病菌，包括铜绿假单胞菌（14例）、肺炎克雷伯菌（5例）、肠杆菌属（3例）和D组链球菌（6例）。临床治愈率和细菌学治愈率分别为90%和91%。5名患者出现副作用，且通常较为轻微。
